Literature DB >> 10486911

Synthesis and preliminary pharmacological evaluation of some cytisine derivatives.

C Canu Boido1, F Sparatore.   

Abstract

Thirty-one N-derivatives of cytisine were prepared in order to modify its pharmacological profile and to obtain compounds of potential therapeutic interest either at a peripheral or central level, particularly as nicotinic ligands with improved ability to cross the blood-brain barrier. Actually, with the introduction of different kinds of substituent on the basic nitrogen of cytisine a variety of activities were observed, both in vivo (analgesic, dopamine antagonism, antihypertensive, inhibition of stress-induced ulcers, antiinflammatory, protection from PAF-induced mortality, hypoglycemic) and in vitro (positive cardio-inotropic, beta-adrenergic antagonism, alpha 1- and alpha 2-antagonism, inhibition of PAF-induced platelet aggregation). Six randomly selected compounds were tested for the ability to recognize a central nicotinic receptor and four of them exhibited Ki values in the range 30-163 nM.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486911     DOI: 10.1016/s0014-827x(99)00049-x

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  5 in total

1.  Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.

Authors:  Loredana Riganti; Cosetta Matteoni; Silvia Di Angelantonio; Andrea Nistri; Annalisa Gaimarri; Fabio Sparatore; Caterina Canu-Boido; Francesco Clementi; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

2.  An uncontrolled trial of cytisine (Tabex) for smoking cessation.

Authors:  Witold Zatonski; Magdalena Cedzynska; Piotr Tutka; Robert West
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

3.  CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.

Authors:  Mariaelvina Sala; Daniela Braida; Luca Pucci; Irene Manfredi; Michael J Marks; Charles R Wageman; Sharon R Grady; Barbara Loi; Sergio Fucile; Francesca Fasoli; Michele Zoli; Bruno Tasso; Fabio Sparatore; Francesco Clementi; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  New arylsparteine derivatives as positive inotropic drugs.

Authors:  Vito Boido; Marcella Ercoli; Michele Tonelli; Federica Novelli; Bruno Tasso; Fabio Sparatore; Elena Cichero; Paola Fossa; Paola Dorigo; Guglielmina Froldi
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 5.  Computer-aided Drug Design Applied to Parkinson Targets.

Authors:  Hamilton M Ishiki; Jose Maria Barbosa Filho; Marcelo S da Silva; Marcus T Scotti; Luciana Scotti
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.